Response by Siontis et al to Letter Regarding Article, "Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States"

Konstantinos C Siontis¹, Xiaosong Zhang², Douglas E Schaubel³, Xiaoxi Yao^{4

5}, Peter A Noseworthy^{1

4}, Nilay D Shah^{4

5}, Rajiv Saran^{2

6}, Brahmajee K Nallamothu^{7

8}

Affiliations

¹ Department of Cardiovascular Medicine (K.C.S., P.A.N.), Mayo Clinic, Rochester, MN.
² Department of Internal Medicine (X.Z., R.S.), University of Michigan, Ann Arbor.
³ Department of Biostatistics, School of Public Health (D.E.S.), University of Michigan, Ann Arbor.
⁴ Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (X.Y., P.A.N., N.D.S.), Mayo Clinic, Rochester, MN.
⁵ Department of Health Sciences Research, Division of Health Care Policy and Research (X.Y., N.D.S.), Mayo Clinic, Rochester, MN.
⁶ Kidney Epidemiology and Cost Center, School of Public Health (R.S.), University of Michigan, Ann Arbor.
⁷ Institute for Healthcare Policy and Innovation (B.K.N.), University of Michigan, Ann Arbor.
⁸ Division of Cardiovascular Medicine, Department of Internal Medicine (B.K.N.), University of Michigan, Ann Arbor.

Comment

Konstantinos C Siontis et al. Circulation. 2019.

. 2019 Mar 19;139(12):1563-1564.

doi: 10.1161/CIRCULATIONAHA.118.039290.

Konstantinos C Siontis¹, Xiaosong Zhang², Douglas E Schaubel³, Xiaoxi Yao^{4

5}, Peter A Noseworthy^{1

4}, Nilay D Shah^{4

5}, Rajiv Saran^{2

6}, Brahmajee K Nallamothu^{7

8}

¹ Department of Cardiovascular Medicine (K.C.S., P.A.N.), Mayo Clinic, Rochester, MN.
² Department of Internal Medicine (X.Z., R.S.), University of Michigan, Ann Arbor.
³ Department of Biostatistics, School of Public Health (D.E.S.), University of Michigan, Ann Arbor.
⁴ Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery (X.Y., P.A.N., N.D.S.), Mayo Clinic, Rochester, MN.
⁵ Department of Health Sciences Research, Division of Health Care Policy and Research (X.Y., N.D.S.), Mayo Clinic, Rochester, MN.
⁶ Kidney Epidemiology and Cost Center, School of Public Health (R.S.), University of Michigan, Ann Arbor.
⁷ Institute for Healthcare Policy and Innovation (B.K.N.), University of Michigan, Ann Arbor.
⁸ Division of Cardiovascular Medicine, Department of Internal Medicine (B.K.N.), University of Michigan, Ann Arbor.

No abstract available

Comment on

Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.
Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK. Siontis KC, et al. Circulation. 2018 Oct 9;138(15):1519-1529. doi: 10.1161/CIRCULATIONAHA.118.035418. Circulation. 2018. PMID: 29954737 Free PMC article.
Letter by Cheen Regarding Article, "Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States".
Cheen MHH. Cheen MHH. Circulation. 2019 Mar 19;139(12):1561-1562. doi: 10.1161/CIRCULATIONAHA.118.038646. Circulation. 2019. PMID: 30883225 No abstract available.